- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 13 Jan 22 424B4 Prospectus supplement with pricing info
- 12 Jan 22 EFFECT Notice of effectiveness
- 5 Jan 22 S-1/A IPO registration (amended)
- 3 Jan 22 S-1/A IPO registration (amended)
- 20 Dec 21 FWP Free writing prospectus
- 10 Dec 21 S-1/A IPO registration (amended)
- 15 Oct 21 S-1/A IPO registration (amended)
-
27 Sep 21 S-1 IPO registration
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Registration Statement on Form S-1 of our report dated May 17, 2021 (except for the effects of the reverse stock split described in Note 2 and Note 11 D, as to which the date is September 27, 2021), with respect to the consolidated financial statements of Hillstream BioPharma, Inc. as of December 31, 2020 and 2019, and for the years then ended (which includes an explanatory paragraph related to the existence of substantial doubt about the Company’s ability to continue as a going concern), and to the reference to us under the heading “Experts” included in this Registration Statement and accompanying prospectus on Form S-1.
/s/ Mayer Hoffman McCann P.C.
San Diego, California
September 27, 2021